[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Sistemas Complejos de Ingeniería\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100555407","effectiveness-and-impact-of-nirsevimab-in-chile-nirse-cl-100555407",false,"NCT06511687","Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)","Effectiveness And Impact of Nirsevimab In A Nationwide Immunization Program During The 2024 Winter Campaign In Chile (Nirse-CL)","Inclusion Criteria:\n\n* Subjects born between October 1st, 2023, to September 31st, 2024.\n* Subjects born with 29 weeks of gestational age (wga) or less who were born between July 1st, 2023 and October 1st, 2023\n* Subjects born with Bronchopulmonary Dysplasia (BPD), 32 or less wga and\u002For a birth weight less than 1·5 kgs born between April 1st, 2023 and October 1st, 2023.\n\nExclusion Criteria:\n\n* No specific criteria has been reported","ALL","4 Years",{"count":19,"type":20},160000,"ESTIMATED","OBSERVATIONAL","The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, and after the implementation of a universal immunization program. The impact of the program on RSV-related health outcomes will also be determined.",[24],"RSV",[24,26],"Nirsevimab","RECRUITING","2024-07-15",{"date":30,"type":31},"2024-07-22","ACTUAL",{"date":33,"type":31},"2024-04-01",{"date":35,"type":20},"2024-10-01",{"name":37,"class":38},"Instituto Sistemas Complejos de Ingeniería","OTHER",""]